Ojo Oluwafemi Adeleke, Ajayi-Odoko Omolola Adenike, Gyebi Gideon Ampoma, Ayokunle Damilare IyinKristi, Ogunlakin Akingbolabo Daniel, Ezenabor Emmanuel Henry, Olanrewaju Adesoji Alani, Agbeye Oluwatobi Deborah, Ogunwale Emmanuel Tope, Rotimi Damilare Emmanuel, Fouad Dalia, Batiha Gaber El-Saber, Adeyemi Oluyomi Stephen
Good Health and Wellbeing Research Clusters (SDG 03), Bowen University, Iwo 232102, Nigeria.
Phytomedicine, Molecular Toxicology, and Computational Biochemistry Research Group, Biochemistry Programme, Bowen University, Iwo 232102, Nigeria.
Life (Basel). 2024 Sep 25;14(10):1222. doi: 10.3390/life14101222.
Alzheimer's disease (AD) is an age-associated neurodegenerative condition marked by amyloid plaques, synaptic dysfunction, and neuronal loss. Besides conventional medical care, herbal therapies, both raw and refined, have attracted researchers for their potential therapeutic effects. As a proof-of-concept, our study combined HPLC-DAD analysis of bioactive constituents, network pharmacology, molecular dynamics (MD), molecular docking, post-MD analysis, and experimental verification to investigate the mechanisms of crude drug formulations as a therapeutic strategy for AD. We identified nine bioactive compounds targeting 188 proteins and 1171 AD-associated genes. Using a Venn diagram, we found 47 overlapping targets, forming "herb-compound-target (HCT)" interaction networks and a protein‒protein interaction (PPI) network. Simulations analyzed binding interactions among the three core targets and their compounds. MD assessed the stability of the best-ranked poses and beneficial compounds for each protein. Among the top 22 hub genes, AChE, BChE, and MAO, ranked 10, 14, and 34, respectively, were selected for further analysis. Two tetraherbal formulations, Form A and Form B, showed notable activity against AChE. Form A exhibited significant ( < 0.0001) inhibitory activity (IC50 = 114.842 ± 2.084 µg/mL) compared to Form B (IC50 = 142.829 ± 4.258 µg/mL), though weaker than galantamine (IC50 = 27.950 ± 0.122 µg/mL). Form B had significant inhibitory effects on BChE (IC50 = 655.860 ± 32.812 µg/mL) compared to Form A (IC50 = 679.718 ± 20.656 µg/mL), but lower than galantamine (IC50 = 23.126 ± 0.683 µg/mL). Both forms protected against Fe2+-mediated brain injury by inhibiting MAO. Docking identified quercetin (-10.2 kcal/mol) and myricetin (-10.1 kcal/mol) for AChE; rutin (-10.6 kcal/mol) and quercetin (-9.7 kcal/mol) for BChE; and kaempferol (-9.1 kcal/mol) and quercetin (-8.9 kcal/mol) for MAO. These compounds were thermodynamically stable based on MD analysis. Collectively, the results offer a scientific rationale for the use of these specifically selected medicinal herbs as AD medications.
阿尔茨海默病(AD)是一种与年龄相关的神经退行性疾病,其特征为淀粉样斑块、突触功能障碍和神经元丢失。除了传统医疗护理外,生用和精制的草药疗法因其潜在治疗效果吸引了研究人员。作为概念验证,我们的研究结合了生物活性成分的高效液相色谱-二极管阵列检测(HPLC-DAD)分析、网络药理学、分子动力学(MD)、分子对接、MD后分析以及实验验证,以研究粗药物配方作为AD治疗策略的机制。我们鉴定出9种靶向188种蛋白质和1171个AD相关基因的生物活性化合物。使用维恩图,我们发现了47个重叠靶点,形成了“草药-化合物-靶点(HCT)”相互作用网络和蛋白质-蛋白质相互作用(PPI)网络。模拟分析了三个核心靶点与其化合物之间的结合相互作用。MD评估了每种蛋白质排名最佳的构象和有益化合物的稳定性。在排名前22的枢纽基因中,分别排名第10、14和34的乙酰胆碱酯酶(AChE)、丁酰胆碱酯酶(BChE)和单胺氧化酶(MAO)被选作进一步分析。两种四草药配方A和配方B对AChE显示出显著活性。与配方B(IC50 = 142.829 ± 4.258 µg/mL)相比,配方A表现出显著(< 0.0001)抑制活性(IC50 = 114.842 ± 2.084 µg/mL),尽管比加兰他敏(IC50 = 27.950 ± 0.122 µg/mL)弱。与配方A(IC50 = 679.718 ± 20.656 µg/mL)相比,配方B对BChE有显著抑制作用(IC50 = 655.860 ± 32.812 µg/mL),但低于加兰他敏(IC50 = 23.126 ± 0.683 µg/mL)。两种配方均通过抑制MAO来预防Fe2+介导的脑损伤。对接鉴定出AChE的槲皮素(-10.2 kcal/mol)和杨梅素(-10.1 kcal/mol);BChE的芦丁(-10.6 kcal/mol)和槲皮素(-9.7 kcal/mol);以及MAO的山奈酚(-9.1 kcal/mol)和槲皮素(-8.9 kcal/mol)。基于MD分析,这些化合物在热力学上是稳定的。总体而言,这些结果为使用这些特别挑选的草药作为AD药物提供了科学依据。